Sublingual Administration of an Adenovirus Serotype 5 (Ad5)-Based Vaccine Confirms Toll-Like Receptor Agonist Activity in the Oral Cavity and Elicits Improved Mucosal and Systemic Cell-Mediated Responses against HIV Antigens despite Preexisting Ad5 Immunity

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Key points are not available for this paper at this time.

Appledorn et al. (2010) studied this question.

View Full Paper

Ask AI

Bookmark